On Jul. 3, 2019, Evotec announced the strategic transaction to acquire Just Biotherapeutics, signed May 20, 2019, had been completed. Evotec acquired Just.Bio to integrate their cutting-edge machine-learning technologies and agile, flexible methods for the design, development, and manufacturing of biologics into Evotec;s drug discovery offerings.

Just.Bio’s approx. 95 employees and its state-of-the-art biologic development and manufacturing site located in Seattle, WA, USA, expanded Evotec’s US footprint.